Navigation Links
New England Biolabs Expands its Distribution Network through Collaborations in India and the Netherlands
Date:4/12/2011

IPSWICH, Mass., April 12, 2011 /PRNewswire/ -- New England Biolabs (NEB), a world leader in the production and supply of reagents for life science research, announces that it has signed exclusive distribution agreements with BIOKE, based in the Netherlands, and Imperial Life Sciences (ILS), based in India.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b)

BIOKE, a Cell Signaling Technology (CST) Europe BV company, is located in Leiden, the Netherlands, and serves Belgium, the Netherlands and Luxemborg. BIOKE supplies reagents for signal transduction, cell culture, molecular biology and laboratory equipment. ILS is a biosupplier company based in Gurgaon, India that currently supplies reagents and instrumentation for genomics, proteomics, cell biology and imaging. By signing agreements in these two regions, NEB's distribution network now extends to 39 companies worldwide.

"NEB maintains an extensive global distribution network to afford our customers efficient access to our high quality reagents throughout the world," states Dr. Peter Nathan, Director of Global Business Development at NEB. "Collaborations with companies such as BIOKE and ILS further strengthen our ability to support the needs of our customers, through their service capabilities, including both ease-of-procurement and excellent technical support."

About NEB

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications, and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs, visit www.neb.com.


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. River Valley Community College and Medical Messenger Team Up to Prepare the Future Nurses of New England
2. Technology Collaboration Between New England Biolabs and Sequenom Delivers First Product for Epigenetics
3. Hospitalists at New England Baptist Hospital Choose MedAptus
4. New England Biolabs Releases JoVE Video Protocol Highlighting Assay to Quantitate 5-hmC in Epigenome
5. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
6. Pescatello Elected to Head New England Biotech Association in 2011-12
7. Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine
8. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
9. Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
10. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
11. New England Biolabs Receives Award to Develop Novel Enzymatic Reagents for Epigenetic Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016  Compass Diversified Holdings (NYSE: CODI ... of leading middle market businesses, announced today its consolidated ... 2016. First Quarter 2016 Highlights , ... or "Cash Flow") of $13.6 million for the first ... $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Myeloid Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Myeloid Leukemia epidemiology, Acute Myeloid ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Dr. Benjamin Stong of Kalos Facial ... treatment. Dr. Stong is double board certified and the only facial plastic surgeon ... of hair loss. Non-surgical therapies such as stem cells can be used to provide ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses ... people all over the United States to thank a nurse who's made a difference ... donate $5 to the American Red Cross of San Diego/Imperial Counties (up to $10,000) ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, ... can weaken the immune system and increase inflammation, both of which raise the risk ... adult congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can ...
(Date:5/5/2016)... N.J. (PRWEB) , ... May 05, 2016 , ... ... patients with cancer, today announced a new collaboration with Imerman Angels to ... cancer anywhere in the world. , “Imerman Angels provides an emotional lifeline to patients ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly 10 million ... up 27 percent since 2012. , The results of the 2015 ASDS Survey on ... in skin cancer treatments and the growing popularity of soft-tissue fillers and body sculpting ...
Breaking Medicine News(10 mins):